Figure 5.

Anti-HIV-1 activity of RB 2121. (a) Inhibition of RT activity in 6-day culture supernatants of infected CEM-4 cells; results represent the mean ± SD of three experiments. RB 2121 was added to CEM-4 cells before (▴) or after (●) HIV-1 infection. Percentage of inhibition obtained with 1 μM zidovudine (■). (b) Infectivity of virions produced in the presence of RB 2121. Regression analysis of RT activity (expressed in cpm) vs. the infectious titer in each supernatant tested: untreated culture (□), cultures treated with 1 μM (▵), 10 μM (■), and 100 μM (○) of RB 2121. (c) Lack of RB 2121 effects on HIV-1-specific activities and viral enzymes. RB 2121 (up to 100 μM) was unable to block virus entry or viral enzymes. All assays were carried out by described techniques (see Materials and Methods). Control drugs gave previously reported values.